A carregar...
Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents
MET is a receptor tyrosine kinase known for its pleiotropic effects in tumorigenesis. Dysregulations of MET expression and/or signaling have been reported and determined to be associated with inferior outcomes in breast cancer patients rendering MET a versatile candidate for targeted therapeutic int...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5634371/ https://ncbi.nlm.nih.gov/pubmed/29042798 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S148604 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|